Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 70500
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Mapk1
Name: mitogen activated protein kinase 1
Acc ID: CHEBI:50924
Term: sorafenib
Definition: A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group.
Chemical ID: MESH:C471405
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Mapk1decreases expressionEXP 6480464CTDsorafenib results in decreased expression of MAPK1 protein modified formPMID:21693435
Mapk1decreases phosphorylationEXP 6480464CTDsorafenib results in decreased phosphorylation of MAPK1 proteinPMID:17341847
Mapk1increases phosphorylationEXP 6480464CTDsorafenib results in increased phosphorylation of MAPK1 proteinPMID:26333016
Mapk1multiple interactionsEXP 6480464CTDSorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 proteinPMID:19338580 PMID:21813464
Mapk1affects phosphorylationISOMAPK1 (Homo sapiens)6480464CTDsorafenib affects the phosphorylation of MAPK1 proteinPMID:19129670
Mapk1decreases activityISOMAPK1 (Homo sapiens)6480464CTDsorafenib results in decreased activity of MAPK1 proteinPMID:22963400
Mapk1decreases phosphorylationISOMAPK1 (Homo sapiens)6480464CTDSorafenib results in decreased phosphorylation of MAPK1 proteinPMID:16255777 PMID:17178882 PMID:17341847 PMID:17991738 PMID:18200035 PMID:18819900 PMID:19139124 PMID:19366808 PMID:19633425 PMID:19878585 PMID:20054642 PMID:20071162 PMID:20473320 PMID:21858812
Mapk1multiple interactionsISOMAPK1 (Homo sapiens)6480464CTD[antrocin analog co-treated with Sorafenib] results in decreased expression of MAPK1 protein; [MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to Sorafenib; [Sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK1 protein; [Sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK1 protein; [Sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [Sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK1 protein; [Sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein; [Sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [Sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; Sorafenib inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK1 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 proteinPMID:16109713 PMID:16959960 PMID:17205056 PMID:17664273 PMID:18819900 PMID:19129670 PMID:20117835 PMID:20301194 PMID:21187475 PMID:22963400 PMID:36565974
Go Back to source page   Continue to Ontology report